Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy

Loren S. Jack, Mohammad Ali Sadiq, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticlepeer-review


Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.

Original languageEnglish (US)
Pages (from-to)302-309
Number of pages8
JournalDevelopments in ophthalmology
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy'. Together they form a unique fingerprint.

Cite this